VACC实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (7 Nov 2023 @ 05:00):

Stats
今日成交量	163 052
平均成交量	731 881
市值	192.73M
EPS	$0.220 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.45
ATR14	$0.559 (17.75%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Pelletier Nadege	Buy	105 000	Share Option (Right to Buy)
2024-01-02	Griffiths Graham	Buy	96 500	Share Option (Right to Buy)
2024-01-02	Enright William	Buy	443 981	Share Option (Right to Buy)
2024-01-02	Brown Gemma	Buy	193 000	Share Option (Right to Buy)
2023-06-26	Scheeren Joseph	Buy	10 000	Ordinary Shares

INSIDER POWER
41.32
Last 95 transactions
Buy: 18 963 250 \| Sell: 20 685 755

音量相关性

長: 0.07 (neutral)

短: 0.52 (weak)

Signal:(49.914) Neutral

Vaccitech plc 相关性

10 最正相关
SVOK	0.919
PAIC	0.901
FORE	0.872
RDUS	0.87
SVAC	0.858
RMRM	0.857
SPRT	0.835
TLGT	0.834
EPZM	0.829
IVA	0.828

10 最负相关
NETE	-0.908
BOCH	-0.876
RAVN	-0.866
AMRB	-0.862
HRMY	-0.852
SBBP	-0.847
MMAC	-0.843
CFMS	-0.835
SFST	-0.829
AEPPZ	-0.827

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Vaccitech plc 相关性 - 货币/商品

-0.46
( neutral )

-0.21
( neutral )

-0.41
( neutral )

-0.30
( neutral )

0.53
( weak )

0.66
( moderate )

Vaccitech plc 财务报表

Annual	2022
营收:	$44.70M
毛利润:	$2.35M (5.26 %)
EPS:	$0.140

FY	2022
营收:	$44.70M
毛利润:	$2.35M (5.26 %)
EPS:	$0.140

FY	2021
营收:	$268 000
毛利润:	$268 000 (100.00 %)
EPS:	$-1 067.56

FY	2020
营收:	$4.82M
毛利润:	$0.00 (0.00 %)
EPS:	$-371.62

Financial Reports:

No articles found.

Vaccitech plc

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.